logo
Plus   Neg
Share
Email

Frontier IP: Exscientia To Get Up To €240 Mln In AI-based Drug Deal With Bayer

Frontier IP Group Plc announced Friday that Artificial Intelligence- driven drug discovery company Exscientia has entered into a collaboration with Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) focused on cardiovascular disease and oncology.

Under the deal terms, Exscientia will initially work on three projects with targets agreed between both parties.

Exscientia may be eligible to receive up to 240 million euros including upfront and research payments, and for meeting near term and clinical milestones. The company may also receive sales royalties.

Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development said, "We are driving forward digital transformation in R&D as we believe that digital technologies such as AI can simplify and speed up the discovery and development of new drugs for patients. The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures."

Exscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron, Rallybio and Evotec.

Frontier IP currently holds a 3.25 percent stake in the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT